Table 2.
Demographics and factors associated with POE.
| No | Age | Sex | Site of cataract surgery | Side | Surgeon grade | Main incision length (mm) | Immunodeficient/Increased infection risk | Previous IVT or Vitrectomy | Intraoperative complication | 10/0 nylon post complication | Intracameral Cefuroxime | Intravitreal antibiotics | Oral Moxifloxacin | Oral Prednisolone and dose | Time to final follow up (days) | Presenting or earliest recorded VA (Snellen) | Final VA (Snellen) | Time of Dx from cataract operation (days) | Post-Dx Vitrectomy | Time to vitrectomy (days) | Microbial growth |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 57 | M | City Road | Left | Consultant | 9.9 | No | Vity | Posterior capsular tear, dropped nucleus, vitreous loss | Yes | Yes | Yes | No | No | 126 | 6/12 | 6/9 | 11 | No | N/A | No growth |
| 2 | 78 | M | Whittington | Left | Consultant | 2.4 | Yes (diabetes, vasculitis on Prednisolone) | No | No | N/A | Yes | Yes | Yes | Yes, 50 mg | 219 | 6/24 | 6/9 | 8 | Yes | 103 | Pseudomonas aeruginosa |
| 3 | 49 | F | City Road | Left | Fellow | 2.4 | No | No | No | N/A | No (subconj Cefuroxime and Betnesol 4 mg instead) | Yes | Yes | Yes, 60 mg | 329 | CF | 6/18 | 3 | No | N/A | Staph. Epidermidis |
| 4 | 73 | F | Queen Mary’s | Right | Consultant | 2.4 | Yes (Rheumatoid arthritis, colon carcinoma) | No | No | N/A | Yes | Yes | Yes | Yes, 60 mg | 415 | HM | 6/5 | 6 | No | N/A | Staph. epidermidis |
| 5 | 82 | F | Queen Mary’s | Right | Registrar | 2.4 | Yes (diabetes, endometrial carcinoma) | No | No | N/A | Yes | Yes | Yes | Yes, 75 mg | 502 | HM | HM | 5 | Yes | 7 | Staph. epidermidis |
| 6 | 87 | F | St Anthony’s | Left | Consultant | 2.4 | No | No | No | N/A | Yes | Yes | Yes | No | 360 | 6/36 (on the day) | 6/12 | 8 | No | N/A | No growth |
| 7 | 56 | M | City Road | Right | Consultant | 2.4 | No | No | No | N/A | Yes | Yes | Yes | No | 1083 | HM (on the day) | 6/6 | 22 | No | N/A | No growth |
| 8 | 58 | M | St Ann’s | Left | Associate specialist | 2.4 | No | No | No | N/A | Yes | Yes | Yes | Yes, 60 mg | 464 | HM | 6/6 | 6 | No | N/A | Strep. sanguinis |
| 9 | 76 | M | Ealing | Right | Associate specialist | 2.4 | Yes (diabetes) | No | No | N/A | Yes | Yes | Yes | No | 223 | 6/18 | 6/12 | 23 | No | N/A | Micrococcus species |
| 10 | 83 | F | Ealing | Left | Consultant | 2.4 | No | No | Anterior capsular tear, vitreous loss | Yes | Yes | Yes | Yes | Yes, 60 mg | 778 | PL | PL | 19 | Yes | 4 | Strep. sanguinis |
| 11 | 66 | F | Ealing | Right | Consultant | 2.4 | Yes (diabetes) | No | No | N/A | Yes | Yes | Yes | Yes, 30 mg | 77 | CF (on the day) | 2/60 | 40 | No | N/A | No growth |
| 12 | 54 | M | Potters Bar | Right | Consultant | 2.4 | No | No | No | N/A | Yes | Yes | Yes | Yes, 50 mg | 713 | 6/18 | 6/9 | 10 | No | N/A | Staph. warneri |
| 13 | 84 | F | City Road | Right | Associate specialist | 2.4 | No | No | No | N/A | Yes | Yes | Yes | No | 247 | 6/18 | 6/9 | 44 | No | N/A | No growth |
| 14 | 57 | F | St George’s | Right | Consultant | 2.4 | No | No | No | N/A | Yes | Yes | Yes | Yes, 60 mg | 687 | CF (on the day) | HM | 3 | Yes | 18 | No specimen obtained |
| 15 | 70 | M | St Ann’s | Right | Fellow | 2.4 | No | Vity | No | N/A | Yes | Yes | Yes | Yes, 60 mg | 439 | HM | 6/6 | 41 | Yes | 1 | No growth |
| 16 | 43 | F | City Road | Right (combined paco+iol+ivt triacense) | Consultant | 2.4 | Yes (prednisolone 40 mg to manage CAU) | No | No | N/A | Yes | Yes | Yes | Yes, 40 mg | 344 | HM | 6/60 | 3 | Yes | 3 | Staph. epidermidis |
| 17 | 69 | M | St George’s | Right | Registrar | 2.4 | No | No | No | N/A | Yes | Yes | Yes | No | 247 | 6/36 | 6/6 | 9 | Yes | 11 | Staph. epidermidis |
| 18 | 71 | M | St George’s | Right (combined paco+iol+ivt Ozurdex) | Consultant | 2.4 | Yes (diabetes, MALT) | No | No | N/A | Yes | Yes | Yes | 80 mg | 117 | HM | NPL | 24 | Yes | 26 | Pseudomonas Aeruginosa |
IVT intravitreal injection therapy, POE post-operative endophthalmitis, VA visual acuity.